Stryker (SYK) 10-Q 24 Jul 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014
Document and Entity Information	'
Document Type	'10-Q
Amendment Flag	'false
Document Period End Date	30-Jun-14
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q2
Trading Symbol	'SYK
Entity Registrant Name	'STRYKER CORP
Entity Central Index Key	'0000310764
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Large Accelerated Filer
Entity Common Stock, Shares Outstanding	378,582,992

Consolidated_Statements_Of_Ear

Consolidated Statements Of Earnings (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net sales	$2,363	$2,212	$4,668	$4,402
Cost of sales	808	730	1,577	1,443
Gross profit	1,555	1,482	3,091	2,959
Research, development and engineering expenses	158	132	308	261
Selling, general and administrative expenses	1,148	1,015	2,353	1,931
Intangible asset amortization	47	36	92	68
Restructuring charges	5	9	10	23
Total operating expenses	1,358	1,192	2,763	2,283
Operating income	197	290	328	676
Other income (expense), net	-30	-21	-54	-32
Earnings before income taxes	167	269	274	644
Income taxes	39	56	76	127
Net earnings	$128	$213	$198	$517
Net earnings per share of common stock:	'	'	'	'
Basic net earnings per share of common stock	$0.34	$0.56	$0.52	$1.36
Diluted net earnings per share of common stock	$0.33	$0.56	$0.51	$1.35
Weighted-average shares outstanding—in millions:	'	'	'	'
Basic	378.8	378	378.5	378.8
Net effect of dilutive employee stock options	3.9	3	4.2	3.2
Diluted	382.7	381	382.7	382
Anti-dilutive shares excluded from the calculation of net effect of dilutive employee stock options	0	2.1	2.5	2.2

Consolidated_Statement_of_Comp

Consolidated Statement of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net earnings	$128	$213	$198	$517
Marketable Securities	4	-5	7	-6
Pension Plans	1	-1	0	2
Hedges	-9	0	-12	0
Financial Statement Translation	-33	20	4	-94
Total other comprehensive income (loss)	-37	14	-1	-98
Comprehensive income	$91	$227	$197	$419

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$1,319	$1,339
Marketable securities	3,426	2,641
Accounts receivable, less allowance of $68 ($72 in 2013)	1,503	1,518
Inventories	'	'
Materials and supplies	254	227
Work in process	104	85
Finished goods	1,229	1,110
Total inventories	1,587	1,422
Deferred income taxes	941	880
Prepaid expenses and other current assets	605	535
Total current assets	9,381	8,335
Property, plant and equipment	'	'
Land, buildings and improvements	693	686
Machinery and equipment	1,933	1,811
Total property, plant and equipment	2,626	2,497
Less allowance for depreciation	1,499	1,416
Net property, plant and equipment	1,127	1,081
Other assets	'	'
Goodwill	4,101	3,844
Other intangibles, net	2,090	1,989
Other	530	494
Total assets	17,229	15,743
Current liabilities	'	'
Accounts payable	337	314
Accrued compensation	399	535
Income taxes	97	131
Dividend payable	116	115
Accrued recall expenses	1,354	772
Accrued expenses and other liabilities	780	765
Current maturities of debt	630	25
Total current liabilities	3,713	2,657
Long-term debt, excluding current maturities	3,237	2,739
Other liabilities	1,277	1,300
Shareholders' equity	'	'
Common stock, $0.10 par value:	38	38
Additional paid-in capital	1,208	1,160
Retained earnings	7,525	7,617
Accumulated other comprehensive income	231	232
Total shareholders' equity	9,002	9,047
Total liabilities & shareholders' equity	$17,229	$15,743

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, except Share data, unless otherwise specified
Accounts receivable, allowance	$68	$72
Common stock, par value	$0.10	$0.10
Common stock, authorized	1,000	1,000
Common stock, outstanding	378	378

Consolidated_Statement_Of_Shar

Consolidated Statement Of Shareholders' Equity (USD $)	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income
In Millions
Balances at December 31, 2013 at Dec. 31, 2013	$9,047	$38	$1,160	$7,617	$232
Net earnings	198	'	'	198	'
Other comprehensive income (loss)	-1	'	'	'	-1
Issuance of 1.6 million shares of common stock under stock option and benefit plans, including $5 excess income tax benefit	9	'	9	'	'
Repurchase and retirement of 0.8 million shares of common stock	61	'	-2	59	'
Share-based compensation	41	'	41	'	'
Cash dividends declared of $0.61 per share of common stock	-231	'	'	-231	'
Balances at June 30, 2014 at Jun. 30, 2014	$9,002	$38	$1,208	$7,525	$231

Consolidated_Statement_Of_Shar1

Consolidated Statement Of Shareholders' Equity (Parenthetical) (USD $)	6 Months Ended	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Issuance of common stock under stock option and benefit plans, shares	1.4	2.1
Issuance of common stock under stock option and benefit plans, excess income tax benefit	$5	$6
Repurchase and retirement of common stock, shares	0.8	0
Cash dividends declared, per share of common stock	$0.61	$1.10

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Operating activities	'	'	'	'
Net earnings	$128	$213	$198	$517
Adjustments to reconcile net earnings to net cash provided by operating activities:	'	'	'	'
Depreciation	47	43	93	81
Amortization of intangible assets	47	36	92	68
Share-based compensation	20	18	41	38
Restructuring charges	5	10	10	24
Sale of inventory stepped up to fair value at acquisition	9	8	14	8
Recall accruals	252	187	582	227
Changes in operating assets and liabilities, net of effects of acquisitions:	'	'	'	'
Accounts receivable	-40	-18	53	-11
Inventories	-59	-25	-120	-63
Accounts payable	-19	-21	11	-30
Accrued expenses and other liabilities	57	82	-142	-70
Income taxes	-81	-141	-137	-150
Other	'	-36	-123	-47
Net cash provided by operating activities	366	356	572	592
Investing activities	'	'	'	'
Acquisitions, net of cash acquired	-185	-62	-457	-662
Purchases of marketable securities	-1,580	-1,843	-2,597	-2,616
Proceeds from sales of marketable securities	804	754	1,812	1,816
Purchases of property, plant and equipment	-54	-47	-124	-96
Net cash used in investing activities	-1,015	-1,198	-1,366	-1,558
Financing activities	'	'	'	'
Proceeds from borrowings	1,469	102	1,813	1,162
Payments on borrowings	-665	-100	-720	-151
Dividends paid	-116	-100	-231	-201
Repurchase and retirement of common stock	-60	'	-60	-250
Other	-40	5	-28	-2
Net cash provided by (used in) financing activities	588	-93	774	558
Effect of exchange rate changes on cash and cash equivalents	-1	-7	0	-16
Change in cash and cash equivalents	($62)	($942)	($20)	($424)

Basis_Of_Presentation

Basis Of Presentation	6 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	BASIS OF PRESENTATION
	General Information
	These statements should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2013. Management believes that the accompanying unaudited Consolidated Financial Statements include all adjustments, including normal recurring items, considered necessary for a fair presentation of the interim periods. However, the results of operations included in such financial statements may not necessarily be indicative of annual results. Certain prior year amounts in our Segment Information in Note 11 have been reclassified to conform with the presentation used in 2014.
	Recently Issued Accounting Pronouncements
	No new accounting pronouncement issued or effective during the year had or is expected to have a material impact on the Consolidated Financial Statements.

Subsequent_Event_Notes

Subsequent Event (Notes)	6 Months Ended
	Jun. 30, 2014
Subsequent Event [Line Items]	'
Subsequent Events [Text Block]	'
	SUBSEQUENT EVENT
	Subsequent to the announcement of our second quarter 2014 operating results on July 17, 2014, we have updated our preliminary estimate of the probable loss to resolve the Rejuvenate and ABG II recall matter based on all information received to date which resulted in a $110 increase to the actuarially determined range of probable loss to resolve the matter to approximately $1,400 to $2,090 before third-party recoveries. Our results for the three months ended June 30, 2014 now include charges to earnings totaling $270, representing the excess of the $1,400 minimum of the range over the previously recorded reserves.

Reclassification_Adjustments_O

Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) (Notes)	6 Months Ended
	Jun. 30, 2014
Reclassification Adjustments Out of Accumulated Other Comprehensive Income [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME (AOCI)
	Changes in and reclassifications out of AOCI in 2014 were as follows:
		Marketable Securities						Pension Plans						Hedges						Financial Statement Translation					Total
		Three Months			Six Months			Three Months			Six Months			Three Months			Six Months			Three Months			Six Months		Three Months			Six Months
	Beginning balance	$	3		$	—		$	(82	)	$	(81	)	$	4		$	7		$	343		$	306	$	268		$	232
	Other comprehensive income (OCI)	7			11			—			(3		)	(12		)	(16		)	(33		)	4		(38		)	(4		)
	Income tax expense on OCI	(1		)	(1		)	—			—			5			7			—			—		4			6
	Reclassifications out of AOCI into:
	Cost of sales	—			—			2			4			—			—			—			—		2			4
	Other (income) expense	(2		)	(4		)	—			—			(3		)	(5		)	—			—		(5		)	(9		)
	Income tax expense (benefit)	—			1			(1		)	(1		)	1			2			—			—		—			2
	Total other comprehensive income	4			7			1			—			(9		)	(12		)	(33		)	4		(37		)	(1		)
	Balance at June 30	$	7		$	7		$	(81	)	$	(81	)	$	(5	)	$	(5	)	$	310		$	310	$	231		$	231

Fair_Value_Measurements_Fair_V

Fair Value Measurements Fair Value Measurements (Notes)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	FAIR VALUE MEASUREMENTS
	Our valuation of our assets and liabilities measured at fair value is:
		Total							Level 1				Level 2					Level 3
		June			31-Dec				June		31-Dec		June		31-Dec			June			31-Dec
		2014			2013				2014		2013		2014		2013			2014			2013
	Cash and cash equivalents	$	1,319		$	1,339			$	1,319	$	1,339	$	—	$	—		$	—		$	—
	Available-for-sale marketable securities
	Corporate and asset-backed debt securities	1,529			1,177				—		—		1,529		1,177			—			—
	Foreign government debt securities	898			845				—		—		898		845			—			—
	United States agency debt securities	402			211				—		—		402		211			—			—
	United States treasury debt securities	491			350				—		—		491		350			—			—
	Certificates of deposit	101			53				—		—		101		53			—			—
	Other	5			5				—		—		5		5			—			—
	Total available-for-sale marketable securities	3,426			2,641				—		—		3,426		2,641			—			—
	Trading marketable securities	77			72				77		72		—		—			—			—
	Foreign currency exchange forward contracts	13			25				—		—		13		25			—			—
		$	4,835		$	4,077			$	1,396	$	1,411	$	3,439	$	2,666		$	—		$	—
	Liabilities:
	Deferred compensation arrangements	$	77		$	72			$	77	$	72	$	—	$	—		$	—		$	—
	Contingent consideration
	Beginning Balance																	59			103
	Losses included in earnings																	—			(5		)
	Settlements																	(14		)	(39		)
	Balance at the end of the period	45			59				—		—		—		—			45			59
	Foreign currency exchange forward contracts	13			2				—		—		13		2			—			—
		$	135		$	133			$	77	$	72	$	13	$	2		$	45		$	59
	We calculate the fair value of our Level 1 and Level 2 instruments based on the exchange traded price of similar or identical instruments, where available, or based on other observable inputs taking into account our credit risk and that of our counterparties. The fair value of our Level 3 liabilities represent milestone payments for acquisitions and is calculated as the net present value of expected cash flows (using a discounted cash flow technique) based on externally provided or obtained inputs, including our probability assessments of the occurrence of triggering events, appropriately discounted considering the uncertainties associated with the obligation. We remeasure this liability each reporting period and record the changes in the fair value in general and administrative expense (for probability of occurrence) and other income (expense) (for changes in time value of money) in earnings. During the period we evaluated but did not change our unobservable input assumptions and fair value techniques used in measuring the fair value of any financial assets or liabilities from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013. There were no significant transfers into or out of any levels that occurred between December 31, 2013 and June 30, 2014.
	Summary of marketable securities:	Amortized Cost							Gross Unrealized Gains				Gross Unrealized Losses					Estimated Fair Value
		June			December				June		December		June		December			June			December
		2014			2013				2014		2013		2014		2013			2014			2013
	Available-for-sale marketable securities:
	Corporate and asset-backed debt securities	$	1,526		$	1,177			$	3	$	1	$	—	$	(1	)	$	1,529		$	1,177
	Foreign government debt securities	894			846				4		—		—		(1		)	898			845
	United States agency debt securities	402			211				—		—		—		—			402			211
	United States treasury debt securities	490			350				1		—		—		—			491			350
	Certificates of deposit	101			53				—		—		—		—			101			53
	Other	5			5				—		—		—		—			5			5
	Total available-for-sale marketable securities	$	3,418		$	2,642			$	8	$	1	$	—	$	(2	)	3,426			2,641
	Trading marketable securities																	77			72
	Total marketable securities																	$	3,503		$	2,713
	Reported as:
	Current assets-marketable securities																	$	3,426		$	2,641
	Noncurrent assets-other																	77			72
																		$	3,503		$	2,713
	The unrealized losses on available-for-sale marketable securities at June 30, 2014 were primarily caused by increases in yields as a result of the rise in government benchmark rates. Less than 1% of our investments in available-for-sale securities had a credit quality rating of less than A2 (Moody's), A (Standard & Poors) and A (Fitch). We do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity; accordingly, we do not consider these investments to be other-than-temporarily impaired at June 30, 2014.
	The cost and estimated fair value of available-for-sale marketable securities at June 30, 2014 by contractual maturity are:
			Cost				Estimated
							Fair Value
	Due in one year or less		$	500			$	500
	Due after one year through three years		284				285
	Due after three years		2,634				2,641
			$	3,418			$	3,426
	The gross unrealized losses and fair value of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position at June 30, 2014 are:
		Corporate and Asset-Backed Debt Securities							Foreign Government Debt Securities				United States Agency Debt Securities					Other						Total
		Less Than 12 Months			Total				Less Than 12 Months		Total		Less Than 12 Months		Total			Less Than 12 Months			Total			Less Than 12 Months		Total
	Number of investments	92			99				3		3		33		33			81			81			209		216
	Fair value	$	200		$	203			$	14	$	14	$	312	$	312		$	21		$	21		$	547	$	550
	Unrealized losses	$	—		$	—			$	—	$	—	$	—	$	—		$	—		$	—		$	—	$	—
	Upon the sale of a security classified as available-for-sale, the security’s specific unrealized gain (loss) is reclassified out of AOCI into earnings based on the specific identification method. Interest and marketable securities income was $5 and $6 for the three months ended June 30, 2014 and 2013, respectively, and $11 for both the six months ended June 30, 2014 and 2013 and is included in other income (expense).

Derivative_Instruments_And_Hed

Derivative Instruments And Hedging Strategies Derivative Instruments and Hedging Strategies (Notes)	6 Months Ended
	Jun. 30, 2014
Derivative [Line Items]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	NOTE 5 - DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES
	We use operational and economic hedges as well as foreign currency exchange forward contracts to manage the impact of currency exchange on earnings and cash flow. During the period we did not change our hedging strategies or objectives from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013. The gross notional and gross fair value amounts of foreign exchange forward contract derivatives designated and non-designated as hedging instruments are:
		30-Jun-14										31-Dec-13
				Fair Value										Fair Value
		Gross Notional		Other Current Assets		Other Assets – Noncurrent		Other Current Liabilities		Other Liabilities – Noncurrent		Gross Notional		Other Current Assets		Other Assets – Noncurrent		Other Current Liabilities		Other Liabilities – Noncurrent
	Designated	$	420	$	1	$	—	$	7	$	1	$	344	$	11	$	1	$	1	$	—
	Non-designated	2,353		12		—		4		1		2,000		10		3		1		—
		$	2,773	$	13	$	—	$	11	$	2	$	2,344	$	21	$	4	$	2	$	—
	We are exposed to credit loss in the event of nonperformance by counterparties on our outstanding forward currency exchange contracts but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of the forward currency exchange contracts at June 30, 2014 and December 31, 2013 was 546 days for each period.
	The net currency exchange rate gains (losses) for the three months ended June 30, 2014 was $0 comprised of gains of $3 recorded in cost of goods sold and losses of ($3) recorded in other income (expense). The net currency exchange rate gains (losses) for the six months ended June 30, 2014 was ($4) comprised of gains of $5 recorded in cost of goods sold and losses of ($9) recorded in other income (expense). The net currency exchange rate losses for both the three and six months ended June 30, 2013 were ($3) and ($4), respectively. These total gains (losses) represent the net impact for both designated and non-designated derivative instruments.
	At June 30, 2014 and December 31, 2013, pretax gains on derivatives designated as hedges of $6 and $12, which are recorded in AOCI, are expected to be reclassified to earnings during the next twelve months. This reclassification is primarily due to the sale of inventory that includes previously hedged purchases. There have been no ineffective portions of derivatives that have resulted in gains or losses in any period.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property, and other matters. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings, the claimants seek damages, as well as other compensatory and equitable relief, that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management has sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, for the resolution of these legal matters is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those projected by management, additional expense may be incurred, which could unfavorably affect future operating results. We are currently self-insured for product liability-related claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.
	In 2010 we received a subpoena from the United States Department of Justice (DOJ) related to the sales and marketing of the OtisKnee device.  The subpoena concerns allegations of violations of federal laws related to sales of a device not cleared by the United States Food and Drug Administration (FDA).  We continue to discuss the settlement of this matter with the DOJ, but there can be no assurance that we will reach a consensual resolution rather than seeking a resolution through the courts. We have recorded charges totaling $80 related to this matter.
	In June 2012 we voluntarily recalled our Rejuvenate and ABG II modular-neck hip stems and terminated global distribution of these hip products. We notified healthcare professionals and regulatory bodies of this recall, which was taken due to potential risks associated with fretting and/or corrosion that may lead to adverse local tissue reactions. Product liability lawsuits relating to this voluntary recall have been filed against us. As previously announced, we intend to reimburse implanted patients for reasonable and customary costs of testing and treatment services, including any necessary revision surgeries. We continue to work with the medical community to evaluate the data and further understand this matter. The ultimate total cost with respect to this matter will depend on many factors that are difficult to predict and may vary materially based on the number of and actual costs of patients seeking testing and treatment services, the number of and actual costs of patients requiring revision surgeries, the number of and actual costs to settle lawsuits filed against us, and the amount of third-party insurance recoveries.  Based on the information that has been received, the actuarially determined range of probable loss to resolve this matter is estimated to be approximately $1,400 to $2,090 before third-party insurance recoveries.  In the three months ended June 30, 2014, we recorded charges to earnings of $270 representing the excess of the $1,400 minimum of the range over the previously recorded reserves. No contingent gain for third-party insurance recoveries was recorded as of June 30, 2014. As noted above, the final outcome of this matter is dependent on many variables that are difficult to predict.  The ultimate cost to entirely resolve this matter may be materially different than the amount of the current estimate and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.
	In 2010 we filed a lawsuit in federal court against Zimmer Holdings, Inc. (Zimmer), alleging that a Zimmer product infringed three of our patents. In rulings issued in August and September 2013, the trial judge upheld the February 2013 jury verdict in our favor, issued a permanent injunction barring Zimmer from making or selling infringing products, and ordered Zimmer to pay us at least $228. Zimmer is appealing this ruling and the ultimate resolution of this matter may differ materially. Accordingly, we have not recorded a contingent gain related to this matter.
	For each of the following legal matters the final outcome is dependent on many variables and cannot be predicted. Accordingly, it is not possible at this time for us to estimate any material loss or range of losses. However, the ultimate cost to resolve these matters could have a material adverse effect on our financial position, results of operations and cash flows.
	In April 2011 lawsuits brought by Hill-Rom Company, Inc. and affiliated entities (Hill-Rom) against us were filed in the United States District Court for the Western District of Wisconsin and the United States District Court for the Southern District of Indiana.  The Wisconsin lawsuit was subsequently transferred to the United States District Court in Indiana. The suits allege infringement under United States patent laws with respect to certain patient handling equipment we manufactured and sold and seek damages and permanent injunctions. We have entered into an agreement settling the first lawsuit, with terms as previously disclosed. The second lawsuit involves nine patents related to electrical network communications for hospital beds. The case has been stayed with respect to six of the patents that are currently under reexamination by the United States Patent Office. With respect to the three remaining patents, all of which have now expired, the Court of Appeals for the Federal Circuit reversed the trial court's grant of summary judgment in our favor and remanded the matter to the trial court for further proceedings. The ultimate resolution of the entire second suit may have no relation to the resolution of the first suit and cannot be predicted; however, the result could have a material adverse effect on our financial position, results of operations and cash flows.
	In 2010 we received a subpoena from the DOJ related to sales and marketing and regulatory matters related to the Stryker PainPump. We have received requests for certain documents in connection with this investigation. The investigation is ongoing and we are fully cooperating with the DOJ regarding this matter.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Acquisitions	'
	ACQUISITIONS
	In June 2014 we announced our intention to acquire the assets of Small Bone Innovations, Inc. (SBi) in an all cash transaction for up to $375. The net cost to Stryker after taking into account the present value of the tax benefits as a result of the asset purchase structure will be up to $285. SBi products are designed and promoted for upper and lower extremity small bone indications, with a focus on small joint replacement. The transaction is subject to customary closing conditions including the expiration or termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and is expected to close in the third quarter of 2014. The acquisition of SBi is expected to enhance our product offerings within our Reconstructive segment.
	In April 2014 we completed the acquisition of Berchtold Holding, AG (Berchtold) for an aggregate purchase price of approximately $172, net of cash acquired. Berchtold, a privately held business with operating facilities in Germany and the United States, sells surgical infrastructure equipment including surgical tables, equipment booms and surgical lighting systems. The acquisition of Berchtold is expected to enhance our product offerings within our MedSurg segment. Intangible assets acquired with Berchtold will be amortized over a weighted-average life of 8 years.
	In March 2014 we completed our acquisition of Patient Safety Technologies, Inc. (PST) for an aggregate purchase price of $120. PST conducts its business through its wholly owned subsidiary, SurgiCount Medical, Inc. PST’s proprietary Safety-Sponge® System and SurgiCount 360™ compliance software help prevent Retained Foreign Objects in the operating room. The acquisition of PST is expected to enhance our product offerings within our MedSurg segment. Intangible assets acquired with PST will be amortized over a weighted-average life of 14 years.
	The acquired net assets of other business acquisitions completed in 2014, including the previously announced acquisition of Pivot Medical, Inc. are in the "Other" column in the table below.
	In December 2013 we acquired MAKO Surgical Corp. (MAKO) for an aggregate purchase price of $1,679. The acquisition of MAKO, combined with our strong history in joint reconstruction, capital equipment (operating room integration and surgical navigation) and surgical instruments, will help further advance the growth of robotic arm assisted surgery. Our combined expertise offers the potential to simplify joint reconstruction procedures, reduce variability and enhance the surgeon and patient experience. The acquisition of MAKO enhances our product offerings within our Reconstructive segment. Intangible assets acquired with MAKO will be amortized over a weighted-average life of 9 years, except for the trade name that is deemed to have an indefinite life. In-process research and development (IPRD) is considered to be an indefinite-lived intangible asset until such time as the research is completed (at which time it becomes a determinable-lived intangible asset) or determined to have no future use (at which time it is impaired).
	The purchase price allocations for Berchtold, PST, MAKO and other smaller acquisitions are based upon preliminary valuations, and our estimates and assumptions are subject to change within the measurement period as the valuations are finalized. We are in the process of verifying data and finalizing information related to these acquisitions to finalize the recording of identifiable intangible assets, deferred income taxes and the corresponding effect on the value of goodwill.
	The allocation of the purchase prices of each acquisition to the acquired net assets is as follows:
		2014			2014			2014			2013
		Berchtold			PST			Other			MAKO
	Purchase price paid	$	172		$	120		$	148		$	1,679
	Tangible assets acquired:
	Inventory	22			7			5			50
	Other assets	38			19			25			174
	Liabilities	(45		)	(33		)	(32		)	(277		)
	Intangible assets:
	Customer relationship	11			33			4			91
	Trade name	7			—			—			24
	Developed technology & patents	32			26			70			231
	IPRD	—			—			2			169
	Goodwill	107			68			74			1,217
		$	172		$	120		$	148		$	1,679

LongTerm_Debt_and_Credit_Facil

Long-Term Debt and Credit Facilities	6 Months Ended
	Jun. 30, 2014
Long-term Debt, Unclassified [Abstract]	'
Long-Term Debt And Credit Facilities	'
	LONG-TERM DEBT AND CREDIT FACILITIES
	Our debt is as follows:
				30-Jun			31-Dec
				2014			2013
	Senior unsecured notes:
		Rate	Due
		3.00%	15-Jan-15	$	500		$	500
		2.00%	30-Sep-16	749			749
		1.30%	1-Apr-18	598			598
		4.38%	15-Jan-20	498			498
		3.38%	15-May-24	595			—
		4.10%	1-Apr-43	394			394
		4.38%	15-May-44	398			—
	Commercial paper			100			—
	Other			35			25
		Total debt		3,867			2,764
		Less current maturities		(630		)	(25		)
		Total long-term debt		$	3,237		$	2,739
	During 2014 we issued commercial paper under the commercial paper program we established in July 2011. The program allows us to have a maximum of $500 in commercial paper outstanding, with maturities up to 397 days from the date of issuance. As of June 30, 2014, outstanding commercial paper totaled $100, the weighted average original maturity of the commercial paper outstanding was approximately 79 days and the weighted average interest rate was 0.27%.
	In May 2014 we sold $600 in senior unsecured notes due 2024 (2024 Notes) and $400 of senior unsecured notes due 2044 (2044 Notes). The 2024 Notes will bear interest at 3.375% per year and, unless previously redeemed, will mature on May 15, 2024. The 2044 Notes will bear interest at 4.375% per year and, unless previously redeemed, will mature on May 15, 2044.
	Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants at June 30, 2014. We have lines of credit, issued by various financial institutions, available to fund our day-to-day operating needs. At June 30, 2014, we had $949 of borrowing capacity available under all of our existing credit facilities. The weighted average interest rate, excluding required fees, for all borrowings was 2.9% at June 30, 2014.
	At June 30, 2014, the total unamortized debt issuance costs incurred in connection with our outstanding notes were $23. The fair value of long-term debt (including current maturities) at June 30, 2014 and December 31, 2013 was $3,795 and $2,790, respectively, based on the quoted interest rates for similar types and amounts of borrowing agreements.

Capital_Stock

Capital Stock	6 Months Ended
	Jun. 30, 2014
Capital Stock Disclosures [Abstract]	'
Capital Stock	'
	CAPITAL STOCK
	In April 2014 we declared a quarterly dividend of $0.305 per share, payable July 31, 2014 to shareholders of record at the close of business on June 30, 2014. In July 2014 we declared a quarterly dividend of $0.305 per share payable October 31, 2014 to shareholders of record at the close of business on September 30, 2014.
	In December of 2012 and 2011, we announced that our Board of Directors had authorized us to purchase up to $405 and $500, respectively, of our common stock (the 2012 and 2011 Repurchase Programs, respectively). The manner, timing and amount of purchases is determined by management based on an evaluation of market conditions, stock price and other factors and is subject to regulatory considerations. Purchases are to be made from time to time in the open market, in privately negotiated transactions or otherwise.
	During 2014 we have repurchased 0.8 million shares at a cost of $60 under the 2011 Repurchase Program. As of June 30, 2014, the maximum dollar value of shares that may yet be purchased under the 2011 Repurchase Program was $218 and we had not made any repurchases pursuant to the 2012 Repurchase Program. At June 30, 2014, the maximum dollar value of shares that may be purchased under the authorized Repurchase Programs was $623.

Restructuring_Charges

Restructuring Charges	6 Months Ended
	Jun. 30, 2014
Restructuring Charges [Abstract]	'
Restructuring Charges	'
	RESTRUCTURING CHARGES
	In recent years, we have incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization. The costs incurred under the ongoing program have generally ranged from $50 to $75 annually. The productivity and cost savings plan was designed to accelerate cost reductions by streamlining management decision making, manufacturing and other work processes to help fund our growth strategy.
	A rollforward of our restructuring liability balance is as follows:
		Total			Severance and Related Costs			Contractual Obligations and Other
	January 1 Balance	$	20		$	10		$	10
	Charges to earnings	10			4			6
	Cash paid	(15		)	(8		)	(7		)
	June 30 Balance	$	15		$	6		$	9

Segment_Information

Segment Information	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	SEGMENT INFORMATION
	Net sales and net earnings by business segment are as follows:
		Reconstructive								MedSurg								Neurotechnology and Spine								Total
		Three Months				Six Months				Three Months				Six Months				Three Months				Six Months				Three Months						Six Months
		2014		2013		2014		2013		2014		2013		2014		2013		2014		2013		2014		2013		2014			2013			2014			2013
	Net sales	$	1,028	$	966	$	2,027	$	1,922	$	905	$	832	$	1,791	$	1,669	$	430	$	414	$	850	$	811	$	2,363		$	2,212		$	4,668		$	4,402
	Segment net earnings	228		231		477		465		151		161		296		322		79		73		165		151		$	458		$	465		$	938		$	938
	Less: other (net of income taxes)
	Other																									(43		)	(59		)	(119		)	(115		)
	Acquisition and integration related charges																									(17		)	(15		)	(30		)	(32		)
	Amortization of intangible assets																									(33		)	(26		)	(64		)	(49		)
	Restructuring and related charges																									(20		)	(10		)	(30		)	(21		)
	Recall charges																									(217		)	(120		)	(489		)	(152		)
	Regulatory matter charges																									—			(22		)	—			(52		)
	Tax matters																									—			—			(8		)	—
	Net earnings																									$	128		$	213		$	198		$	517
	Other than assets associated with the acquisitions that are discussed in greater detail in Note 7, there were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for the year ended December 31, 2013.

Reclassification_Adjustments_O1

Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) (Tables)	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	'
		Marketable Securities						Pension Plans						Hedges						Financial Statement Translation					Total
		Three Months			Six Months			Three Months			Six Months			Three Months			Six Months			Three Months			Six Months		Three Months			Six Months
	Beginning balance	$	3		$	—		$	(82	)	$	(81	)	$	4		$	7		$	343		$	306	$	268		$	232
	Other comprehensive income (OCI)	7			11			—			(3		)	(12		)	(16		)	(33		)	4		(38		)	(4		)
	Income tax expense on OCI	(1		)	(1		)	—			—			5			7			—			—		4			6
	Reclassifications out of AOCI into:
	Cost of sales	—			—			2			4			—			—			—			—		2			4
	Other (income) expense	(2		)	(4		)	—			—			(3		)	(5		)	—			—		(5		)	(9		)
	Income tax expense (benefit)	—			1			(1		)	(1		)	1			2			—			—		—			2
	Total other comprehensive income	4			7			1			—			(9		)	(12		)	(33		)	4		(37		)	(1		)
	Balance at June 30	$	7		$	7		$	(81	)	$	(81	)	$	(5	)	$	(5	)	$	310		$	310	$	231		$	231

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosure [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
		Total							Level 1				Level 2					Level 3
		June			31-Dec				June		31-Dec		June		31-Dec			June			31-Dec
		2014			2013				2014		2013		2014		2013			2014			2013
	Cash and cash equivalents	$	1,319		$	1,339			$	1,319	$	1,339	$	—	$	—		$	—		$	—
	Available-for-sale marketable securities
	Corporate and asset-backed debt securities	1,529			1,177				—		—		1,529		1,177			—			—
	Foreign government debt securities	898			845				—		—		898		845			—			—
	United States agency debt securities	402			211				—		—		402		211			—			—
	United States treasury debt securities	491			350				—		—		491		350			—			—
	Certificates of deposit	101			53				—		—		101		53			—			—
	Other	5			5				—		—		5		5			—			—
	Total available-for-sale marketable securities	3,426			2,641				—		—		3,426		2,641			—			—
	Trading marketable securities	77			72				77		72		—		—			—			—
	Foreign currency exchange forward contracts	13			25				—		—		13		25			—			—
		$	4,835		$	4,077			$	1,396	$	1,411	$	3,439	$	2,666		$	—		$	—
	Liabilities:
	Deferred compensation arrangements	$	77		$	72			$	77	$	72	$	—	$	—		$	—		$	—
	Contingent consideration
	Beginning Balance																	59			103
	Losses included in earnings																	—			(5		)
	Settlements																	(14		)	(39		)
	Balance at the end of the period	45			59				—		—		—		—			45			59
	Foreign currency exchange forward contracts	13			2				—		—		13		2			—			—
		$	135		$	133			$	77	$	72	$	13	$	2		$	45		$	59
Marketable Securities [Table Text Block]	'
	Summary of marketable securities:	Amortized Cost							Gross Unrealized Gains				Gross Unrealized Losses					Estimated Fair Value
		June			December				June		December		June		December			June			December
		2014			2013				2014		2013		2014		2013			2014			2013
	Available-for-sale marketable securities:
	Corporate and asset-backed debt securities	$	1,526		$	1,177			$	3	$	1	$	—	$	(1	)	$	1,529		$	1,177
	Foreign government debt securities	894			846				4		—		—		(1		)	898			845
	United States agency debt securities	402			211				—		—		—		—			402			211
	United States treasury debt securities	490			350				1		—		—		—			491			350
	Certificates of deposit	101			53				—		—		—		—			101			53
	Other	5			5				—		—		—		—			5			5
	Total available-for-sale marketable securities	$	3,418		$	2,642			$	8	$	1	$	—	$	(2	)	3,426			2,641
	Trading marketable securities																	77			72
	Total marketable securities																	$	3,503		$	2,713
	Reported as:
	Current assets-marketable securities																	$	3,426		$	2,641
	Noncurrent assets-other																	77			72
																		$	3,503		$	2,713
Investments Classified by Contractual Maturity Date [Table Text Block]	'
	The cost and estimated fair value of available-for-sale marketable securities at June 30, 2014 by contractual maturity are:
			Cost				Estimated
							Fair Value
	Due in one year or less		$	500			$	500
	Due after one year through three years		284				285
	Due after three years		2,634				2,641
			$	3,418			$	3,426
Schedule of Unrealized Loss on Investments [Table Text Block]	'
		Corporate and Asset-Backed Debt Securities							Foreign Government Debt Securities				United States Agency Debt Securities					Other						Total
		Less Than 12 Months			Total				Less Than 12 Months		Total		Less Than 12 Months		Total			Less Than 12 Months			Total			Less Than 12 Months		Total
	Number of investments	92			99				3		3		33		33			81			81			209		216
	Fair value	$	200		$	203			$	14	$	14	$	312	$	312		$	21		$	21		$	547	$	550
	Unrealized losses	$	—		$	—			$	—	$	—	$	—	$	—		$	—		$	—		$	—	$	—

Recovered_Sheet1

Derivative Instruments and Hedging Strategies (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	'
		30-Jun-14										31-Dec-13
				Fair Value										Fair Value
		Gross Notional		Other Current Assets		Other Assets – Noncurrent		Other Current Liabilities		Other Liabilities – Noncurrent		Gross Notional		Other Current Assets		Other Assets – Noncurrent		Other Current Liabilities		Other Liabilities – Noncurrent
	Designated	$	420	$	1	$	—	$	7	$	1	$	344	$	11	$	1	$	1	$	—
	Non-designated	2,353		12		—		4		1		2,000		10		3		1		—
		$	2,773	$	13	$	—	$	11	$	2	$	2,344	$	21	$	4	$	2	$	—

Acquisitions_Acquisitions_Tabl

Acquisitions Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Schedule of Purchase Price Allocation [Table Text Block]	'
	llows:
		2014			2014			2014			2013
		Berchtold			PST			Other			MAKO
	Purchase price paid	$	172		$	120		$	148		$	1,679
	Tangible assets acquired:
	Inventory	22			7			5			50
	Other assets	38			19			25			174
	Liabilities	(45		)	(33		)	(32		)	(277		)
	Intangible assets:
	Customer relationship	11			33			4			91
	Trade name	7			—			—			24
	Developed technology & patents	32			26			70			231
	IPRD	—			—			2			169
	Goodwill	107			68			74			1,217
		$	172		$	120		$	148		$	1,679

LongTerm_Debt_and_Credit_Facil1

Long-Term Debt and Credit Facilities (Tables)	6 Months Ended
	Jun. 30, 2014
Long-term Debt, Unclassified [Abstract]	'
Maturities Of Long-Term Debt Disclosures	'
				30-Jun			31-Dec
				2014			2013
	Senior unsecured notes:
		Rate	Due
		3.00%	15-Jan-15	$	500		$	500
		2.00%	30-Sep-16	749			749
		1.30%	1-Apr-18	598			598
		4.38%	15-Jan-20	498			498
		3.38%	15-May-24	595			—
		4.10%	1-Apr-43	394			394
		4.38%	15-May-44	398			—
	Commercial paper			100			—
	Other			35			25
		Total debt		3,867			2,764
		Less current maturities		(630		)	(25		)
		Total long-term debt		$	3,237		$	2,739

Restructuring_Charges_Tables

Restructuring Charges (Tables)	6 Months Ended
	Jun. 30, 2014
Restructuring Charges [Abstract]	'
Restructuring Charges	'
		Total			Severance and Related Costs			Contractual Obligations and Other
	January 1 Balance	$	20		$	10		$	10
	Charges to earnings	10			4			6
	Cash paid	(15		)	(8		)	(7		)
	June 30 Balance	$	15		$	6		$	9

Segment_Information_Tables

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Sales and Other Financial Information by Business Segment	'
		Reconstructive								MedSurg								Neurotechnology and Spine								Total
		Three Months				Six Months				Three Months				Six Months				Three Months				Six Months				Three Months						Six Months
		2014		2013		2014		2013		2014		2013		2014		2013		2014		2013		2014		2013		2014			2013			2014			2013
	Net sales	$	1,028	$	966	$	2,027	$	1,922	$	905	$	832	$	1,791	$	1,669	$	430	$	414	$	850	$	811	$	2,363		$	2,212		$	4,668		$	4,402
	Segment net earnings	228		231		477		465		151		161		296		322		79		73		165		151		$	458		$	465		$	938		$	938
	Less: other (net of income taxes)
	Other																									(43		)	(59		)	(119		)	(115		)
	Acquisition and integration related charges																									(17		)	(15		)	(30		)	(32		)
	Amortization of intangible assets																									(33		)	(26		)	(64		)	(49		)
	Restructuring and related charges																									(20		)	(10		)	(30		)	(21		)
	Recall charges																									(217		)	(120		)	(489		)	(152		)
	Regulatory matter charges																									—			(22		)	—			(52		)
	Tax matters																									—			—			(8		)	—
	Net earnings																									$	128		$	213		$	198		$	517

Subsequent_Event_Details

Subsequent Event (Details) (Rejuvenate and ABG II Voluntary Recall [Member], USD $)	Jul. 24, 2014	Jun. 30, 2014
In Millions, unless otherwise specified
Subsequent Event [Line Items]	'	'
Estimated Litigation Liability	$110	$270
Minimum	'	'
Subsequent Event [Line Items]	'	'
Loss Contingency, Estimate of Possible Loss	'	1,400
Maximum	'	'
Subsequent Event [Line Items]	'	'
Loss Contingency, Estimate of Possible Loss	'	$2,090

Reclassification_Adjustments_O2

Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) Reclassification Adjustments Out of Accumulated Other Comprehensive Income (AOCI) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	$268	'	$232	'
Other comprehensive income (OCI)	-38	'	-4	'
Income taxes	39	56	76	127
Other comprehensive income (loss)	-37	14	-1	-98
Net Income (Loss) Attributable to Parent	128	213	198	517
Accumulated Other Comprehensive Income (Loss), Net of Tax	231	'	231	'
Marketable Securities	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	3	'	'	'
Other comprehensive income (OCI)	7	'	11	'
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	-1	'	-1	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	7	'	7	'
Pension Plans	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	-82	'	-81	'
Other comprehensive income (OCI)	0	'	-3	'
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax	0	'	0	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	-81	'	-81	'
Hedges	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	4	'	7	'
Other comprehensive income (OCI)	-12	'	-16	'
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax	5	'	7	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	-5	'	-5	'
Financial Statement Translation	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	343	'	306	'
Other comprehensive income (OCI)	-33	'	4	'
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	0	'	0	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	310	'	310	'
Accumulated Other Comprehensive Income	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Tax	4	'	6	'
Other comprehensive income (loss)	'	'	-1	'
Reclassification out of Accumulated Other Comprehensive Income [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Income taxes	0	'	2	'
Other comprehensive income (loss)	-37	'	-1	'
Reclassification out of Accumulated Other Comprehensive Income [Member] | Marketable Securities	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Income taxes	0	'	1	'
Other comprehensive income (loss)	4	'	7	'
Reclassification out of Accumulated Other Comprehensive Income [Member] | Pension Plans	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Income taxes	-1	'	-1	'
Other comprehensive income (loss)	1	'	'	'
Reclassification out of Accumulated Other Comprehensive Income [Member] | Hedges	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Income taxes	1	'	2	'
Other comprehensive income (loss)	-9	'	-12	'
Reclassification out of Accumulated Other Comprehensive Income [Member] | Financial Statement Translation	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Income taxes	0	'	0	'
Other comprehensive income (loss)	-33	'	4	'
Cost of Sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	2	'	4	'
Cost of Sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Marketable Securities	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax	0	'	0	'
Cost of Sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Pension Plans	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax	2	'	4	'
Cost of Sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Hedges	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax	0	'	0	'
Cost of Sales [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Financial Statement Translation	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax	0	'	0	'
Other Income (expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	-5	'	-9	'
Other Income (expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Marketable Securities	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	-2	'	-4	'
Other Income (expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Pension Plans	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Tax	0	'	0	'
Other Income (expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Hedges	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax	-3	'	-5	'
Other Income (expense) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Financial Statement Translation	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax	$0	'	$0	'

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013
Interest Income (Expense), Net	'	$3	$2
Investment Income, Nonoperating	5	11	6
Marketable Securities, Gain (Loss)	'	$8	$9
Asset-backed Securities [Member] | Standard & Poor's, A Rating [Member]	'	'	'
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2	'	1.00%	'
Asset-backed Securities [Member] | Fitch, A Rating [Member]	'	'	'
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2	'	1.00%	'
Asset-backed Securities [Member] | Moody's, A2 Rating [Member]	'	'	'
Percentage Of Company's Investments With Credit Quality Rating Less Than Single A And A2	'	1.00%	'

Fair_Value_Measurements_Valuat

Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) (USD $)	6 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Investments, Fair Value Disclosure	$13	$25	'
Derivative Asset	4,835	4,077	'
Liabilities:	77	72	'
Business Combination, Contingent Consideration, Liability	45	59	'
Derivative Liability	13	2	'
Liabilities, Fair Value Disclosure, Recurring	135	133	'
Available-for-sale Securities [Member]	'	'	'
Investments, Fair Value Disclosure	3,426	2,641	'
Available-for-sale Securities [Member] | Corporate and asset-backed debt securities	'	'	'
Investments, Fair Value Disclosure	1,529	1,177	'
Available-for-sale Securities [Member] | Foreign Government Debt Securities [Member]	'	'	'
Investments, Fair Value Disclosure	898	845	'
Available-for-sale Securities [Member] | US Government Agencies Debt Securities [Member]	'	'	'
Investments, Fair Value Disclosure	402	211	'
Available-for-sale Securities [Member] | US Treasury Securities [Member]	'	'	'
Investments, Fair Value Disclosure	491	350	'
Available-for-sale Securities [Member] | Certificates of Deposit [Member]	'	'	'
Investments, Fair Value Disclosure	101	53	'
Available-for-sale Securities [Member] | Other Security Investments [Member]	'	'	'
Investments, Fair Value Disclosure	5	5	'
Trading Securities [Member]	'	'	'
Investments, Fair Value Disclosure	77	72	'
Fair Value, Inputs, Level 1 [Member]	'	'	'
Derivative Asset	1,396	1,411	'
Liabilities:	77	72	'
Liabilities, Fair Value Disclosure, Recurring	77	72	'
Fair Value, Inputs, Level 1 [Member] | Trading Securities [Member]	'	'	'
Investments, Fair Value Disclosure	77	72	'
Fair Value, Inputs, Level 2 [Member]	'	'	'
Investments, Fair Value Disclosure	13	25	'
Derivative Asset	3,439	2,666	'
Derivative Liability	13	2	'
Liabilities, Fair Value Disclosure, Recurring	13	2	'
Fair Value, Inputs, Level 2 [Member] | Available-for-sale Securities [Member]	'	'	'
Investments, Fair Value Disclosure	3,426	2,641	'
Fair Value, Inputs, Level 2 [Member] | Available-for-sale Securities [Member] | Corporate and asset-backed debt securities	'	'	'
Investments, Fair Value Disclosure	1,529	1,177	'
Fair Value, Inputs, Level 2 [Member] | Available-for-sale Securities [Member] | Foreign Government Debt Securities [Member]	'	'	'
Investments, Fair Value Disclosure	898	845	'
Fair Value, Inputs, Level 2 [Member] | Available-for-sale Securities [Member] | US Government Agencies Debt Securities [Member]	'	'	'
Investments, Fair Value Disclosure	402	211	'
Fair Value, Inputs, Level 2 [Member] | Available-for-sale Securities [Member] | US Treasury Securities [Member]	'	'	'
Investments, Fair Value Disclosure	491	350	'
Fair Value, Inputs, Level 2 [Member] | Available-for-sale Securities [Member] | Certificates of Deposit [Member]	'	'	'
Investments, Fair Value Disclosure	101	53	'
Fair Value, Inputs, Level 2 [Member] | Available-for-sale Securities [Member] | Other Security Investments [Member]	'	'	'
Investments, Fair Value Disclosure	5	5	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Business Combination, Contingent Consideration, Liability	45	59	103
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset and Liability, Gain (Loss) Included in Earnings	'	5	'
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset and Liability, Settlements	14	39	'
Liabilities, Fair Value Disclosure, Recurring	$45	$59	'

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets and Liabilities Measured At Fair Value On A Recurring Basis Using Unobservable Inputs (Level 3)) (Details) (USD $)	6 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Marketable Securities	$3,503	$2,713
Available-for-sale Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	3,418	2,642
Available-for-sale Securities, Gross Unrealized Gain	8	1
Available-for-sale Securities, Gross Unrealized Loss	'	2
Marketable Securities	3,426	2,641
Available-for-sale Securities [Member] | Asset-backed Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	1,526	1,177
Available-for-sale Securities, Gross Unrealized Gain	3	1
Available-for-sale Securities, Gross Unrealized Loss	'	1
Marketable Securities	1,529	1,177
Available-for-sale Securities [Member] | Foreign Government Debt Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	894	846
Available-for-sale Securities, Gross Unrealized Gain	4	'
Available-for-sale Securities, Gross Unrealized Loss	'	1
Marketable Securities	898	845
Available-for-sale Securities [Member] | US Government Agencies Debt Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	402	211
Marketable Securities	402	211
Available-for-sale Securities [Member] | US Treasury Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	490	350
Available-for-sale Securities, Gross Unrealized Gain	1	'
Marketable Securities	491	350
Available-for-sale Securities [Member] | Certificates of Deposit [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	101	53
Marketable Securities	101	53
Available-for-sale Securities [Member] | Other Security Investments [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	5	5
Marketable Securities	5	5
Trading Securities [Member]	'	'
Marketable Securities	77	72
Available-for-sale Securities [Member]	'	'
Marketable Securities	3,426	2,641
Other Assets [Member]	'	'
Marketable Securities	$77	$72

Fair_Value_Measurements_Market

Fair Value Measurements (Marketable Securities) (Details) (USD $)	6 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Marketable Securities	$3,503	$2,713
Other Assets [Member]	'	'
Marketable Securities	77	72
Available-for-sale Securities [Member]	'	'
Marketable Securities	3,426	2,641
Available-for-sale Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	3,418	2,642
Available-for-sale Securities, Gross Unrealized Gain	8	1
Available-for-sale Securities, Gross Unrealized Loss	'	2
Marketable Securities	3,426	2,641
Available-for-sale Securities [Member] | Asset-backed Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	1,526	1,177
Available-for-sale Securities, Gross Unrealized Gain	3	1
Available-for-sale Securities, Gross Unrealized Loss	'	1
Marketable Securities	1,529	1,177
Available-for-sale Securities [Member] | Foreign Government Debt Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	894	846
Available-for-sale Securities, Gross Unrealized Gain	4	'
Available-for-sale Securities, Gross Unrealized Loss	'	1
Marketable Securities	898	845
Available-for-sale Securities [Member] | US Government Agencies Debt Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	402	211
Marketable Securities	402	211
Available-for-sale Securities [Member] | US Treasury Securities [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	490	350
Available-for-sale Securities, Gross Unrealized Gain	1	'
Marketable Securities	491	350
Available-for-sale Securities [Member] | Certificates of Deposit [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	101	53
Marketable Securities	101	53
Available-for-sale Securities [Member] | Other Security Investments [Member]	'	'
Available-for-sale Securities, Amortized Cost Basis	5	5
Marketable Securities	5	5
Trading Securities [Member]	'	'
Marketable Securities	$77	$72

Fair_Value_Measurements_Net_Ca

Fair Value Measurements (Net Carrying Value And Estimated Fair Value Of Available-For-Sale Marketable Securities) (Details) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]	'
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis	$500
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value	500
Available for sale Securities, Debt Maturities, After One Through Three Years, Amortized Cost	284
Available for sale Securities, Debt Maturities, After One Through Three Years, Fair Value	285
Available for sale Securities, Debt Maturities, After Three Years, Amortized Cost	2,634
Available for sale Securities, Debt Maturities, After Three Years, Fair Value	2,641
Available-for-sale Securities, Debt Maturities, Amortized Cost Basis	3,418
Available-for-sale Securities, Debt Securities	$3,426

Fair_Value_Measurements_Unreal

Fair Value Measurements (Unrealized Losses And Fair Value Of Investments With Unrealized Losses) (Details) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year	209
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions	216
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$547
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	550
Asset-backed Securities [Member]	'
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year	92
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions	99
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	200
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	203
Foreign Government Debt Securities [Member]	'
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year	3
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions	3
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	14
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	14
US Government Agencies Debt Securities [Member]	'
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year	33
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions	33
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	312
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	312
Other Debt Obligations [Member]	'
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Less than One Year	81
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions	81
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	21
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$21

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Strategies (Narrative) (Details) (USD $)

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Foreign Exchange Contract [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Other Income [Member]

Other Income [Member]

Other Income [Member]

Other Income [Member]

Foreign currency transaction losses

'

'

$0

$4

'

'

($3)

($5)

($3)

$3

$9

$4

Maximum Term (Days)

'546 days

'546 days

'

'

'

'

'

'

'

'

'

'

Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months

'

'

'

'

$6

$12

'

'

'

'

'

'

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Strategies (Forward Currency Exchange Contracts) (Details) (Foreign Exchange Contract [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Notional Amount	$2,773	$2,344
Designated as Hedging Instrument [Member]	'	'
Notional Amount	420	344
Not Designated as Hedging Instrument [Member]	'	'
Notional Amount	2,353	2,000
Other Current Assets	'	'
Derivative Asset, Fair Value, Gross Asset	13	21
Other Current Assets | Designated as Hedging Instrument [Member]	'	'
Derivative Asset, Fair Value, Gross Asset	1	11
Other Current Assets | Not Designated as Hedging Instrument [Member]	'	'
Derivative Asset, Fair Value, Gross Asset	12	10
Other Assets b Noncurrent	'	'
Derivative Asset, Fair Value, Gross Asset	0	4
Other Assets b Noncurrent | Designated as Hedging Instrument [Member]	'	'
Derivative Asset, Fair Value, Gross Asset	0	1
Other Assets b Noncurrent | Not Designated as Hedging Instrument [Member]	'	'
Derivative Asset, Fair Value, Gross Asset	0	3
Other Current Liabilities	'	'
Derivative Liability, Fair Value, Gross Liability	11	2
Other Current Liabilities | Designated as Hedging Instrument [Member]	'	'
Derivative Liability, Fair Value, Gross Liability	7	1
Other Current Liabilities | Not Designated as Hedging Instrument [Member]	'	'
Derivative Liability, Fair Value, Gross Liability	4	1
Other Liabilities b Noncurrent	'	'
Derivative Liability, Fair Value, Gross Liability	2	0
Other Liabilities b Noncurrent | Designated as Hedging Instrument [Member]	'	'
Derivative Liability, Fair Value, Gross Liability	1	0
Other Liabilities b Noncurrent | Not Designated as Hedging Instrument [Member]	'	'
Derivative Liability, Fair Value, Gross Liability	$1	$0

Contingencies_Narrative_Detail

Contingencies (Narrative) (Details) (USD $)	Jun. 30, 2014	Jul. 24, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Sep. 30, 2013
In Millions, unless otherwise specified		Rejuvenate and ABG II Voluntary Recall [Member]	Rejuvenate and ABG II Voluntary Recall [Member]	Electrical Network Communications, Hospital Beds [Member]	Patents Under Reexamination [Member]	Number of Remaining Patents [Member]	Minimum	Maximum	Zimmer Product Infringement [Member]
				patent	patent	patent	Rejuvenate and ABG II Voluntary Recall [Member]	Rejuvenate and ABG II Voluntary Recall [Member]
Loss Contingency Accrual, at Carrying Value	$80	'	'	'	'	'	'	'	'
Loss Contingency, Estimate of Possible Loss	'	'	'	'	'	'	1,400	2,090	'
Loss Contingency, Damages Awarded, Value	'	'	'	'	'	'	'	'	'228
Estimated Litigation Liability	'	$110	$270	'	'	'	'	'	'
Loss Contingency, Number of Patents	'	'	'	9	6	3	'	'	'

Acquisitions_Narrative_Details

Acquisitions (Narrative) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Small Bone Innovations [Member]	'
Business Acquisition [Line Items]	'
Purchase price paid	$375
Business Acquisition, Cost of Acquired Entity after tax benefits	285
Berchtold	'
Business Acquisition [Line Items]	'
Purchase price paid	172
Inventory	22
Other assets	38
Liabilities	-45
Goodwill	107
PST	'
Business Acquisition [Line Items]	'
Purchase price paid	120
Inventory	7
Other assets	19
Liabilities	33
Goodwill	68
Other	'
Business Acquisition [Line Items]	'
Purchase price paid	148
Inventory	5
Other assets	25
Liabilities	32
Goodwill	74
MAKO	'
Business Acquisition [Line Items]	'
Purchase price paid	1,679
Inventory	50
Other assets	174
Liabilities	277
Goodwill	1,217
Customer relationship | Berchtold	'
Business Acquisition [Line Items]	'
Tangible assets acquired:	'8 years
Intangible assets:	11
Customer relationship | PST	'
Business Acquisition [Line Items]	'
Tangible assets acquired:	'14 years
Intangible assets:	33
Customer relationship | Other	'
Business Acquisition [Line Items]	'
Intangible assets:	4
Customer relationship | MAKO	'
Business Acquisition [Line Items]	'
Tangible assets acquired:	'9 years
Intangible assets:	91
Trade name | Berchtold	'
Business Acquisition [Line Items]	'
Intangible assets:	7
Trade name | PST	'
Business Acquisition [Line Items]	'
Intangible assets:	0
Trade name | Other	'
Business Acquisition [Line Items]	'
Intangible assets:	0
Trade name | MAKO	'
Business Acquisition [Line Items]	'
Intangible assets:	24
Developed technology & patents | Berchtold	'
Business Acquisition [Line Items]	'
Intangible assets:	32
Developed technology & patents | PST	'
Business Acquisition [Line Items]	'
Intangible assets:	26
Developed technology & patents | Other	'
Business Acquisition [Line Items]	'
Intangible assets:	70
Developed technology & patents | MAKO	'
Business Acquisition [Line Items]	'
Intangible assets:	231
IPRD | Berchtold	'
Business Acquisition [Line Items]	'
Intangible assets:	0
IPRD | PST	'
Business Acquisition [Line Items]	'
Intangible assets:	0
IPRD | Other	'
Business Acquisition [Line Items]	'
Intangible assets:	2
IPRD | MAKO	'
Business Acquisition [Line Items]	'
Intangible assets:	$169

Acquisitions_Acquisitions_Allo

Acquisitions Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of The Trauson Acquisition (Details) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Berchtold	'
Purchase price paid	$172
Inventory	22
Other assets	38
Liabilities	45
Goodwill	107
PST	'
Purchase price paid	120
Inventory	7
Other assets	19
Liabilities	-33
Goodwill	68
Other	'
Purchase price paid	148
Inventory	5
Other assets	25
Liabilities	-32
Goodwill	74
MAKO	'
Purchase price paid	1,679
Inventory	50
Other assets	174
Liabilities	-277
Goodwill	1,217
Customer relationship | Berchtold	'
Intangible assets:	11
Customer relationship | PST	'
Intangible assets:	33
Customer relationship | Other	'
Intangible assets:	4
Customer relationship | MAKO	'
Intangible assets:	91
Trade name | Berchtold	'
Intangible assets:	7
Trade name | PST	'
Intangible assets:	0
Trade name | Other	'
Intangible assets:	0
Trade name | MAKO	'
Intangible assets:	24
Developed technology & patents | Berchtold	'
Intangible assets:	32
Developed technology & patents | PST	'
Intangible assets:	26
Developed technology & patents | Other	'
Intangible assets:	70
Developed technology & patents | MAKO	'
Intangible assets:	231
IPRD | Berchtold	'
Intangible assets:	0
IPRD | PST	'
Intangible assets:	0
IPRD | Other	'
Intangible assets:	2
IPRD | MAKO	'
Intangible assets:	$169

LongTerm_Debt_and_Credit_Facil2

Long-Term Debt and Credit Facilities (Narrative) (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Commercial paper	$500	'
Debt Instrument, Maturity	'397 days	'
Commercial Paper, weighted average interest rate	0.27%	'
Line of Credit Facility, Remaining Borrowing Capacity	949	'
Long-term debt, weighted-average interest rate	2.90%	'
Unamortized Debt Issuance Expense	23	'
Debt Instrument, Fair Value Disclosure	3,795	2,790
3.00% senior unsecured notes, due January 15, 2015	'	'
Debt Instrument, Interest Rate, Stated Percentage	3.00%	'
Senior Unsecured Notes 2.00% due 2016 [Member]	'	'
Debt Instrument, Interest Rate, Stated Percentage	2.00%	'
1.30% senior unsecured notes, due April 1, 2018	'	'
Debt Instrument, Interest Rate, Stated Percentage	1.30%	'
4.375% senior unsecured notes, due January 15, 2020	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%	'
3.375% senior unsecured notes due 2024 [Member]	'	'
Credit facility	600	'
Debt Instrument, Interest Rate, Stated Percentage	3.38%	'
4.10% senior unsecured notes, due April 1, 2043	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.10%	'
4.375% senior unsecured notes due 2044 [Member]	'	'
Credit facility	$400	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%	'
Commercial paper	'	'
Debt Instrument, Maturity	'79 days	'

LongTerm_Debt_and_Credit_Facil3

Long-Term Debt and Credit Facilities (Maturities Of Long-Term Debt Disclosures) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Commercial paper	$100	$0
Other	35	25
Total debt	3,867	2,764
Less current maturities	-630	-25
Total long-term debt	3,237	2,739
3.00% senior unsecured notes, due January 15, 2015	'	'
Debt Instrument, Interest Rate, Stated Percentage	3.00%	'
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	500	500
Senior Unsecured Notes 2.00% due 2016 [Member]	'	'
Debt Instrument, Interest Rate, Stated Percentage	2.00%	'
Senior unsecured notes repayable in year three	749	749
1.30% senior unsecured notes, due April 1, 2018	'	'
Debt Instrument, Interest Rate, Stated Percentage	1.30%	'
Senior unsecured notes repayable in year four	598	598
4.375% senior unsecured notes, due January 15, 2020	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%	'
Senior unsecured notes repayable after year five	498	498
3.375% senior unsecured notes due 2024 [Member]	'	'
Debt Instrument, Interest Rate, Stated Percentage	3.38%	'
Senior unsecured notes repayable after year five	595	0
4.10% senior unsecured notes, due April 1, 2043	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.10%	'
Senior unsecured notes repayable after year five	394	394
4.375% senior unsecured notes due 2044 [Member]	'	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%	'
Senior unsecured notes repayable after year five	$398	$0

LongTerm_Debt_and_Credit_Facil4

Long-Term Debt and Credit Facilities Long-Term Debt and Credit Facilities (Parentheticals) (Details)	Jun. 30, 2014
3.00% senior unsecured notes, due January 15, 2015	'
Debt Instrument, Interest Rate, Stated Percentage	3.00%
2.00% senior unsecured notes, due September 30, 2016	'
Debt Instrument, Interest Rate, Stated Percentage	2.00%
1.30% senior unsecured notes, due April 1, 2018	'
Debt Instrument, Interest Rate, Stated Percentage	1.30%
4.375% senior unsecured notes, due January 15, 2020	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%
3.375% senior unsecured notes due 2024 [Member]	'
Debt Instrument, Interest Rate, Stated Percentage	3.38%
4.10% senior unsecured notes, due April 1, 2043	'
Debt Instrument, Interest Rate, Stated Percentage	4.10%
4.375% senior unsecured notes due 2044 [Member]	'
Debt Instrument, Interest Rate, Stated Percentage	4.38%

Capital_Stock_Narrative_Detail

Capital Stock (Narrative) (Details) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended		6 Months Ended	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2014	Dec. 31, 2011
				2012 $405.0 Million Repurchase Agreement [Member]	2011 $500.0 Million Repurchase Agreement [Member]	2011 $500.0 Million Repurchase Agreement [Member]
Cash dividends declared, per share of common stock	$0.31	$0.61	$1.10	'	'	'
Stock Repurchase Program, Authorized Amount	'	'	'	$405	'	$500
Stock Repurchased and Retired During Period, Shares	'	0.8	0	'	0.8	'
Repurchase and retirement of 0.8 million shares of common stock	'	61	'	'	0	'
Stock Repurchase Program, Remaining Authorized Repurchase Amount	'	$623	'	'	$218	'

Restructuring_Charges_Narrativ

Restructuring Charges (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Restructuring charges	$5	$10	$10	$24
Cash paid	50	'	'	'
Historical Restructuring Cost Per Year, Maximum	75	'	'	'
Severance and Related Costs	'	'	'	'
Restructuring charges	'	'	4	'
Contractual Obligations and Other	'	'	'	'
Restructuring charges	'	'	$6	'

Company_Recorded_Restructuring

Company Recorded Restructuring Charges (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
January 1 Balance	'	'	$20	'
Charges to earnings	5	10	10	24
Cash paid	'	'	-15	'
June 30 Balance	15	'	15	'
Severance and Related Costs	'	'	'	'
January 1 Balance	'	'	10	'
Charges to earnings	'	'	4	'
Cash paid	'	'	-8	'
June 30 Balance	6	'	6	'
Contractual Obligations and Other	'	'	'	'
January 1 Balance	'	'	10	'
Charges to earnings	'	'	6	'
Cash paid	'	'	-7	'
June 30 Balance	$9	'	$9	'

Segment_Information_Sales_And_

Segment Information (Sales And Other Financial Information By Business Segment) (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net sales	$2,363	$2,212	$4,668	$4,402
Segment net earnings	197	290	328	676
Acquisition and integration related charges	17	15	30	32
Amortization of intangible assets	-33	-26	-64	-49
Restructuring and related charges	-20	-10	-30	-21
Recall charges	-217	-120	-489	-152
Regulatory matter charges	'	-22	'	-52
Tax matters	'	'	-8	'
Net earnings	128	213	198	517
Reconstructive	'	'	'	'
Net sales	1,028	966	2,027	1,922
Segment net earnings	228	231	477	465
MedSurg	'	'	'	'
Net sales	905	832	1,791	1,669
Segment net earnings	151	161	296	322
Neurotechnology and Spine	'	'	'	'
Net sales	430	414	850	811
Segment net earnings	79	73	165	151
Total	'	'	'	'
Net sales	2,363	2,212	4,668	4,402
Segment net earnings	458	465	938	938
Corporate and Other [Member]	'	'	'	'
Segment net earnings	($43)	($59)	($119)	($115)